CX-839-008 – A Phase III, Randomized,Placebo Controlled Study Of ATEZOLIZUMAB(ANTI-PD-L1 ANTIBODY) As Monotherapy And In Combination With Platinum Chemotherapy In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma.
1. WHAT TYPE OF CANCER? WHAT STAGE?
Renal Cell Cancer.
2. WHO IS ELIGIBLE?
Patients with disease progression after first-line therapy.
3. HOW WILL I BE TREATED?
Adds CB-839 (a drug that inhibits tumor cell nutrient uptake) to treated with Cabozantinib (a small molecule tyrosine kinase inhibitor).
For Physicians: More information about this specific trial at clinicaltrials.gov